Clin2
NCT04643418Possibly a fitRecruiting

Study drug for advanced solid tumors you can’t remove

Solid Tumor, Unspecified, Adult

Part of Cancer clinical trials.

This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
81 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older and able to sign consent in your local language.
  • Your cancer must be a solid tumor confirmed by tests, with measurable spots on scans, and it must be unresectable (not removable by surgery).
  • Your general health/strength must be good enough (performance status of 2 or less).
  • You need to have recovered from side effects of prior treatment (especially nerve problems must be mild or better), and enough time must have passed since your last therapy.
  • You must not have certain blood test or heart rhythm issues: liver enzymes and bilirubin must be below set limits, kidney function must be adequate, and QTc on an EKG must be under 470 ms.
  • You must not have uncontrolled symptoms that need urgent relief (like immediate surgery or radiotherapy) or severe baseline nerve damage, and you must be able to communicate and follow study visits.
  • If you are female, you must not be pregnant or breast-feeding and must not plan pregnancy during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05789602Recruiting· Phase 1
Study drug for advanced solid tumors in adults

This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.

Beijing, Beijing Municipality
NCT06240546Recruiting· Phase 1
Study of LPM6690176 for advanced solid tumors

This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.

Beijing
NCT05652855Not yet recruiting· Phase 1/Phase 2
Drug trial for advanced solid tumors that stopped responding

This early-stage study tests an investigational drug (MHB088C) in adults with advanced or metastatic solid cancers that have gotten worse or can’t be treated with standard options. It aims to see if the drug is safe and can shrink tumors or control the cancer.

Gold Coast, Queensland
NCT06985355Recruiting· Phase 1/Phase 2
Testing MHB046C injection for advanced solid tumors

This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.

Guangzhou, Guangdong
NCT06825494Recruiting· Phase 1/Phase 2
Study of a new drug for advanced solid tumors

This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.

Hefei, Anhui
NCT06554795Recruiting· Phase 1/Phase 2
Testing DB-1419 for advanced solid tumors

This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.

Los Angeles, California

Hear when a new Solid Tumor, Unspecified, Adult trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.